Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation

Recruiting now · Not applicable

Conditions studied: Atrial Fibrillation

In brief

Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) has limited success. The superior vena cava (SVC) has been identified as one of the most common non-pulmonary vein triggers for PAF. It is estimated that SVC isolation (SVCI) could improve the clinical results for patients with PAF. However, results from previous studies about SVCI remain controversial. It is possible that safety concerns for SVCI outweigh its benefits and lead to inadequate ablation. To address this issue, the introduction of a quantitative ablation index (AI) for SVCI may provide a solution. The goal of this prospective, randomized controlled trial is to test the efficacy and safety of quantitative SVCI in addition to PVI in PAF. Participants with PAF will be randomly assigned to either PVI group or PVI+ quantitative SVCI group in a 1:1 ratio and will be followed up for 12 months. The main questions it aims to answer are: 1. Evaluate the efficacy of PVI+SVCI guided by quantitative AI. 2. Assess the safety of PVI+SVCI guided by quantitative AI. The primary end point is treatment success at 3 months after the index ablation. The secondary end points include treatment success at 12 months, and safety outcomes.

Key facts

Study ID

NCT05908955

Run by

Chinese Academy of Medical Sciences, Fuwai Hospital

People needed

290

Starts

2024-03-17

Expected to finish

2025-12-31

Last updated by the study team

2025-02-14

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Symptomatic paroxysmal AF that are unresponsive to antiarrhythmic drugs (one or more than one).
• Willing to undergo catheter ablation for AF.
• Age: 40-75 years old.

You may not qualify if…

• History of any type of catheter ablation for cardiac arrhythmias.
• History of any type of thoracic surgery, including cardiac surgery.
• History of malignant tumors.
• History of permanent pacemaker implantation.
• Peripherally inserted central catheter for long-term
• Heart failure (left ventricular ejection fraction ≤40% or NYHA class III\~IV).
• Sinus node dysfunction
• Allergy to contrast agents.
• Pregnancy or lactation.
• Age: <40yrs or >75yrs.

Where it is running

• Chinese Academy of Medical Science, Fuwai hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.